A quick reminder that Bill Ackman's worst nightmare is still very much a thing

It's time to check in on a Wall Street disaster.
Valeant Pharmaceuticals will report earnings on February 28, and analysts up and down Wall Street remain skeptical that the company can get back on its feet after a nightmarish run.
Here's what Wells Fargo analyst David Maris wrote about it in a recent note:
In 2017, we expect Valeant will try to distance itself from the reality of its current business and current business trends. In our experience, management teams that try to do this usually tal